Restoring harmony to failing biological systems
The first therapeutic platform for multi-RNA combination medicines that act in synergy.
Backed by:
The biggest unmet needs in medicine rarely have a single biological driver. They emerge from complex, interconnected biological networks.
Conditions such as fibrosis, heart failure and neurodegeneration involve multiple disease pathways operating in parallel and interacting across cell types. This creates a need for coordinated intervention across complementary mechanisms.
Our platform is built for this: novel delivery of combined mRNAs and siRNAs paired with a predictive design loop to identify combinations that produce effects no single intervention can achieve alone.
Beyond single targetsUp to 99%
lung targeting in mice
2.2x
lung enrichment over lead lung delivery in primates
1450
genes accessible by combination only
<12 months
from no targets to high efficacy across in vivo and ex-vivo models
Where conventional drugs can lack precision or breadth, multi-RNA approaches can address exactly what needs to be targeted.
Simultaneously and Precisely.
Three integrated capabilities.
01 —
Multi-RNA combinations
A systematic process for identifying and combining mRNA and siRNA targets that work synergistically, turning multiple disease pathways up or down in concert.
02 —
Novel delivery system
A proprietary carrier platform for targeted delivery of multiple RNAs, safe for repeated dosing and room-temperature stable.
03 —
Computational platform
Building an engine that learns from every experiment we run, predicting which targets, ratios and delivery parameters will produce the strongest synergy. Every new data point makes the next prediction better.
Fibrosis of the lung is our proving ground.
Our combination has been validated across IPF patient cell lines, human PCLS and mouse bleomycin models. The same combination works in liver and kidney fibrosis.
Taking multi-RNA to the clinic.
An interdisciplinary team across chemistry, biology and computational science, with advisors who took RNA medicines to market at BioNTech and Moderna.